Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases

Abstract Background Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. Methods We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at Institut Curie Hospitals, with a focus on patients with brain metastases. Results This study included 99 patients treated through the French Early Access Program to SG from May 2021 to January 2023. Median age was 55 years 26–89, N = 8 patients (8%) had BRCA1/2 mutation, N = 12 (12%) de novo stage IV disease and N = 31 (31%) brain metastases. Patients had previously received a median of two 1–10 lines of treatment in advanced setting. After a median follow-up of 9.7 months, the median progression-free survival (PFS) and overall survival (OS) were 3.9 months (95%CI3.4–5.0) and 8.6 months (95%CI7.1–11.9), respectively, while objective response rate was 29% (95%CI21–39). Among patients with brain metastases, median PFS and OS were 3.7 months (95%CI2.6–6.2) and 6.7 months (95%CI6.3–NR), respectively, with intracranial tumor responses. Dose reductions were required in N = 17 patients (17%) within a median of three 2–11 cycles, due to gastrointestinal toxicity ( N = 6; 6%), hematological toxicity ( N = 9; 9%) including febrile neutropenia ( N = 2; 2%), liver enzyme elevation ( N = 1; 1%), and physical deterioration ( N = 1; 1%). There was no related death to SG. Conclusions The observed response rate and safety of SG are consistent with the results of the ASCENT trial, with efficacy observed in patients with brain metastases, but observed PFS and OS are numerically shorter.